These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 4483533)

  • 1. The effect of antacid administration on the absorption and metabolism of levodopa.
    Leon AS; Spiegel HE
    J Clin Pharmacol New Drugs; 1972 Jul; 12(7):263-7. PubMed ID: 4483533
    [No Abstract]   [Full Text] [Related]  

  • 2. Studies on the metabolism and excretion of L-3,4-dihydroxyphenylalanine (L-DOPA) in human beings by gas chromatography.
    Imai K; Sugiura M; Kubo H; Tamura Z; Oya K
    Chem Pharm Bull (Tokyo); 1972 Apr; 20(4):759-64. PubMed ID: 5045616
    [No Abstract]   [Full Text] [Related]  

  • 3. Metabolism of levodopa in patients with Parkinson's disease. Radioactive and fluorometric assays.
    Morgan JP; Bianchine JR; Spiegel HE; Rivera-Calimlim L; Hersey RM
    Arch Neurol; 1971 Jul; 25(1):39-44. PubMed ID: 5146410
    [No Abstract]   [Full Text] [Related]  

  • 4. Catecholamine metabolism during oral administration of levodopa.
    Hinterberger H; Andrews CJ
    Arch Neurol; 1972 Mar; 26(3):245-52. PubMed ID: 5061285
    [No Abstract]   [Full Text] [Related]  

  • 5. Dose-related alterations in metabolism of levodopa: possible mechanism for hypotensive effect.
    Kochar MS; Itskovitz HD; Sasse EA; Baker JD; Doumas BT
    J Clin Pharmacol; 1974; 14(8):448-54. PubMed ID: 4851433
    [No Abstract]   [Full Text] [Related]  

  • 6. Metabolism and absorption of L-3,4 dihydroxyphenylalanine in patients with Parkinson's disease.
    Bianchine JR; Calimlim LR; Morgan JP; Dujuvne CA; Lasagna L
    Ann N Y Acad Sci; 1971 Jul; 179():126-40. PubMed ID: 5285373
    [No Abstract]   [Full Text] [Related]  

  • 7. Variation of levodopa metabolism with gastrointestinal absorption site.
    Sandler M; Ruthven CR; Goodwin BL; Hunter KR; Stern GM
    Lancet; 1974 Feb; 1(7851):238-40. PubMed ID: 4130247
    [No Abstract]   [Full Text] [Related]  

  • 8. Levodopa in Parkinsonism: potentiation of central effects with a peripheral inhibitor.
    Papavasiliou PS; Cotzias GC; Düby SE; Steck AJ; Fehling C; Bell MA
    N Engl J Med; 1972 Jan; 286(1):8-14. PubMed ID: 4550085
    [No Abstract]   [Full Text] [Related]  

  • 9. Biochemical investigations in patients with Parkinson's disease treated with L-dopa.
    Jequier E; Dufresne JJ
    Neurology; 1972 Jan; 22(1):15-21. PubMed ID: 5061836
    [No Abstract]   [Full Text] [Related]  

  • 10. Peripheral aromatic L-amino acids decarboxylase inhibitor in parkinsonism. II. Effect on metabolism of L-2- 14 C-dopa.
    Bianchine JR; Messiha FS; Hsu TH
    Clin Pharmacol Ther; 1972; 13(4):584-94. PubMed ID: 5042372
    [No Abstract]   [Full Text] [Related]  

  • 11. A clinico-biochemical correlation in a Parkinsonian patient treated with levodopa and decarboxylase inhibitor (Ro 4-4602). A model study.
    Sroka H; Eichhorn F; Rutenberg A; Radwan H; Bornstein B
    J Neurol Sci; 1972 Sep; 17(1):61-8. PubMed ID: 5057196
    [No Abstract]   [Full Text] [Related]  

  • 12. Development of a screening test for L-dopa and its metabolites in urine.
    Routh JI; Bannow RE
    Clin Chem; 1971 Sep; 17(9):872-4. PubMed ID: 5571486
    [No Abstract]   [Full Text] [Related]  

  • 13. Metabolic interactions of pyridoxine, levodopa, and carbidopa in Parkinson's disease.
    Mars H
    Trans Am Neurol Assoc; 1973; 98():241-5. PubMed ID: 4784941
    [No Abstract]   [Full Text] [Related]  

  • 14. Levodopa, carbidopa, and pyridoxine in Parkinson disease. Metabolic interactions.
    Mars H
    Arch Neurol; 1974 Jun; 30(6):444-7. PubMed ID: 4827061
    [No Abstract]   [Full Text] [Related]  

  • 15. Excretion of L-dopa and its metabolites in urine of Parkinson's disease patients receiving L-dopa therapy.
    Routh JI; Bannow RE; Fincham RW; Stoll JL
    Clin Chem; 1971 Sep; 17(9):867-71. PubMed ID: 5571485
    [No Abstract]   [Full Text] [Related]  

  • 16. Slowly absorbed L-dopa preparation in the treatment of parkinsonism.
    Laitinen LV
    Acta Neurol Scand; 1973; 49(3):331-8. PubMed ID: 4747020
    [No Abstract]   [Full Text] [Related]  

  • 17. Oral L-dopa treatment of parkinsonism.
    Andén NE; Carlsson A; Kerstell J; Magnusson T; Olsson R; Roos BE; Steen B; Steg G; Svanborg A; Thieme G; Werdinius B
    Acta Med Scand; 1970 Apr; 187(4):247-55. PubMed ID: 4911257
    [No Abstract]   [Full Text] [Related]  

  • 18. [The effect of alpha-DOPA on the dynamics of urinary excretion of DOPA, catecholamines and their metabolites in healthy subjects and in patients with parkinsonism].
    Matlina ESh; Kandel' EI; Vasil'ev VN; Iadgarov IS; Bol'shakova TD
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1973; 73(2):205-9. PubMed ID: 4743269
    [No Abstract]   [Full Text] [Related]  

  • 19. [Treatment of Parkinsonism with L-dopa--with special reference to clinical effects, side effects and urinary metabolites of catecholamines].
    Uono M; Tanabe H; Yano Y; Nakao K
    No To Shinkei; 1970 Sep; 22(9):1091-101. PubMed ID: 5536082
    [No Abstract]   [Full Text] [Related]  

  • 20. Excretion of dopa metabolites.
    Kott E; Bornstein B; Eichhorn F
    N Engl J Med; 1971 Feb; 284(7):395. PubMed ID: 5539935
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.